Friday, October 30, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 30, 2025

Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical

View original at finance.yahoo.com
“Amid this scenario, industry players like Veracyte, IDEXX Laboratories and Intuitive Surgical have adapted well to changing consumer preferences and have been witnessing an uptrend in their stock prices.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • IDEXX Laboratories' 2025 sales consensus estimate is $4.28 billion, representing 9.9% growth

    80% confidence

  • The Zacks Medical Instruments industry carries a Zacks Industry Rank #161, placing it in the bottom 33% of 243 Zacks industries

    80% confidence

  • Intuitive Surgical holds a Zacks Rank #2 (Buy)

    80% confidence

  • The Zacks Medical Instruments industry is trading at a forward 12-month P/E of 30.36X, compared with the broader industry's 21.29X and the S&P 500's 23.42X

    80% confidence

  • Global generative AI in the healthcare market is valued at $2.64 billion in 2025 and is expected to witness a CAGR of 35.2% through 2034

    80% confidence

  • Veracyte's 2025 EPS consensus estimate is $1.65, representing 38.7% growth from 2024

    80% confidence

  • IDEXX Laboratories' 2025 EPS consensus estimate is $12.93, representing 21.2% growth

    80% confidence

  • MedTech deal value surged to $92.8 billion in 2025, the highest level in more than a decade, driven by three mega-deals

    80% confidence

  • Global AI in the healthcare market is projected to witness a CAGR of 44% from 2025 to 2032

    80% confidence

  • The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1

    80% confidence

  • The Medical Instruments industry's five-year P/E range has been as high as 40.76X, as low as 25.73X, with a median of 32.28X

    80% confidence

  • Veracyte's 2025 sales consensus estimate is $508.6 million, representing 14.1% growth from 2024

    80% confidence

  • Global growth is expected to remain at 3.2% in 2025 and 3.1% in 2026, below the pre-pandemic average of 3.7%

    80% confidence

  • Global headline inflation is expected to decline to 4.2% in 2025 and to 3.7% in 2026

    80% confidence

  • Veracyte holds a Zacks Rank #1 (Strong Buy)

    80% confidence

  • IDEXX Laboratories holds a Zacks Rank #2 (Buy)

    80% confidence

  • The application of AI in the diagnostics space is growing enormously, with the market expected to witness a CAGR of 20.4% by 2034

    80% confidence

  • Intuitive Surgical's 2025 EPS consensus estimate is $8.65, representing 17.9% growth year-over-year

    80% confidence

  • Overall MedTech M&A activity remained below historical norms, with only 46 announced deals through November 30, 2025

    80% confidence

  • Intuitive Surgical's 2025 sales consensus estimate is $9.92 billion, representing 18.7% growth from 2024

    80% confidence

  • Zacks top stock-picking strategies have averaged gains of +48.4%, +50.2%, and +56.7% per year since 2000, versus the S&P's +7.7% average annual gain

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com
Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical — Source | Via News | Finance Via News